Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
About this trial
The purpose of this study is to determine the incidence and predictors of high degree or complete atrioventricular block (AVB) (paroxysmal or persistent) in patients with new-onset persistent left bundle branch block (NOP-LBBB) following transcatheter aortic valve implantation (TAVI) and to evaluate the usefulness of the Reveal LINQ® insertable Cardiac Monitor (ICM) (Medtronic, Inc., Minneapolis, USA) for the detection of significant arrhythmias in patients with NOP-LBBB following TAVI.
Eligibility criteria
Qualifiers
None
Disqualifiers
Failure to provide informed consent
Baseline pacemaker/defibrillator or pacemaker/defibrillator implanted during the hospitalization period following the TAVI procedure
Pre-existing complete LBBB
Patients with a life-expectancy of less than 2 years
Trial design
Treatments tested in this trial
- Implantable loop recorders system Reveal ICM LINQ®,
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov